U.S. Markets closed

KOF to Buy Stake in Coke's Bottler

Zacks Equity Research

The Coca-Cola FEMSA S.A.B. de C.V. (KOF) has entered into a definitive agreement to buy 51% stake in The Coca-Cola Company’s (KO) franchise bottler in Philippines, Coca-Cola Bottlers Philippines, Inc. (:CCBPI), for $688.5 million in cash.

The transaction is expected to close in early 2013. Per the agreement, Mexico’s Coca-Cola FEMSA reserves the option to acquire the remaining 49% of Coke’s Philippine bottling plant at any time during the following seven years. The largest Coke bottler also has an option to sell back its 51% share to The Coca-Cola Company in the sixth year.

The deal will expand Coca-Cola FEMSA’s presence beyond Latin America to the fast growing emerging market of Philippines. Coca-Cola’s products are very popular in this country, which boasts one of the highest per capita consumption rates of Coca-Cola products. CCBPI is expected to generate revenues of approximately $1.1 billion in 2012. The bottler, which has 23 production plants, is expected to sell approximately 535 million unit cases of beverages in the year.

The Coca-Cola Company has ownership interests in many other bottling operations, including Coca-Cola Enterprises Inc., (CCE), Coca-Cola Hellenic Bottling Company S.A. (CCH), and Coca-Cola Amatil Ltd. In October 2010, the company acquired Coca-Cola Enterprises’ North American bottling and distribution operations. In December 2011, the company acquired Coca-Cola Great Plains Bottling Company and in February 2012, it acquired bottling operations in Vietnam and Cambodia from Coca-Cola Sabco Limited (Sabco). In June 2012, Coca-Cola acquired bottling operations in Guatemala.

Our Recommendation

We currently have Neutral recommendation on both The Coca-Cola Company and Coca-Cola FEMSA. Both the stocks carry a Zacks#3 Rank (short term ‘Hold’ rating).

Read the Full Research Report on CCE

Read the Full Research Report on KO

Read the Full Research Report on CCH

Read the Full Research Report on KOF

Zacks Investment Research

More From Zacks.com